Literature DB >> 23468489

Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Margaret E Ackerman1, Anne-Sophie Dugast, Elizabeth G McAndrew, Stephen Tsoukas, Anna F Licht, Darrell J Irvine, Galit Alter.   

Abstract

While development of an HIV vaccine that can induce neutralizing antibodies remains a priority, decades of research have proven that this is a daunting task. However, accumulating evidence suggests that antibodies with the capacity to harness innate immunity may provide some protection. While significant research has focused on the cytolytic properties of antibodies in acquisition and control, less is known about the role of additional effector functions. In this study, we investigated antibody-dependent phagocytosis of HIV immune complexes, and we observed significant differences in the ability of antibodies from infected subjects to mediate this critical effector function. We observed both quantitative differences in the capacity of antibodies to drive phagocytosis and qualitative differences in their FcγR usage profile. We demonstrate that antibodies from controllers and untreated progressors exhibit increased phagocytic activity, altered Fc domain glycosylation, and skewed interactions with FcγR2a and FcγR2b in both bulk plasma and HIV-specific IgG. While increased phagocytic activity may directly influence immune activation via clearance of inflammatory immune complexes, it is also plausible that Fc receptor usage patterns may regulate the immune response by modulating downstream signals following phagocytosis--driving passive degradation of internalized virus, release of immune modulating cytokines and chemokines, or priming of a more effective adaptive immune response.

Mesh:

Substances:

Year:  2013        PMID: 23468489      PMCID: PMC3648186          DOI: 10.1128/JVI.03403-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection.

Authors:  K K Van Rompay; C J Berardi; S Dillard-Telm; R P Tarara; D R Canfield; C R Valverde; D C Montefiori; K S Cole; R C Montelaro; C J Miller; M L Marthas
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

Review 2.  Anti-HIV-1 ADCC.

Authors:  D S Tyler; H K Lyerly; K J Weinhold
Journal:  AIDS Res Hum Retroviruses       Date:  1989-12       Impact factor: 2.205

3.  Predominance of the IgG1 subclass in the hypergammaglobulinemia observed in pre-AIDS and AIDS.

Authors:  J Kekow; G Hobusch; W L Gross
Journal:  Cancer Detect Prev       Date:  1988

4.  Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients.

Authors:  D N Forthal; G Landucci; R Haubrich; B Keenan; B D Kuppermann; J G Tilles; J Kaplan
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

5.  Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages.

Authors:  Vincent Holl; Stéphane Hemmerter; Renaud Burrer; Sylvie Schmidt; Alain Bohbot; Anne-Marie Aubertin; Christiane Moog
Journal:  J Immunol       Date:  2004-11-15       Impact factor: 5.422

6.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

Review 7.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

8.  Increased levels of galactose-deficient IgG in sera of HIV-1-infected individuals.

Authors:  Jennifer S Moore; Xueling Wu; Rose Kulhavy; Milan Tomana; Jan Novak; Zina Moldoveanu; Rhubell Brown; Paul A Goepfert; Jiri Mestecky
Journal:  AIDS       Date:  2005-03-04       Impact factor: 4.177

9.  Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection.

Authors:  L A Sawyer; D A Katzenstein; R M Hendry; E J Boone; L K Vujcic; C C Williams; S L Zeger; A J Saah; C R Rinaldo; J P Phair
Journal:  AIDS Res Hum Retroviruses       Date:  1990-03       Impact factor: 2.205

10.  Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors.

Authors:  R Clynes; J S Maizes; R Guinamard; M Ono; T Takai; J V Ravetch
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

View more
  57 in total

1.  Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers.

Authors:  Jennifer I Lai; Anna F Licht; Anne-Sophie Dugast; Todd Suscovich; Ickwon Choi; Chris Bailey-Kellogg; Galit Alter; Margaret E Ackerman
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

2.  Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001.

Authors:  Matthew R Costa; Justin Pollara; Regina Whitney Edwards; Michael S Seaman; Miroslaw K Gorny; David C Montefiori; Hua-Xin Liao; Guido Ferrari; Shan Lu; Shixia Wang
Journal:  J Virol       Date:  2016-10-28       Impact factor: 5.103

3.  A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Authors:  Amber Dunkel; Shixue Shen; Celia C LaBranche; David Montefiori; James P McGettigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-05-05       Impact factor: 2.205

4.  Short communication: Fc gamma receptors IIa and IIIa genetic polymorphisms do not predict HIV-1 disease progression in Kenyan women.

Authors:  Julie F Weis; R Scott McClelland; Walter Jaoko; Kishor N Mandaliya; Julie Overbaugh; Susan M Graham
Journal:  AIDS Res Hum Retroviruses       Date:  2014-11-13       Impact factor: 2.205

5.  Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.

Authors:  Zelda Euler; Galit Alter
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 6.  Systems serology for evaluation of HIV vaccine trials.

Authors:  Margaret E Ackerman; Dan H Barouch; Galit Alter
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors.

Authors:  Saheli Sadanand; Jishnu Das; Amy W Chung; Matthew K Schoen; Sophie Lane; Todd J Suscovich; Hendrik Streeck; Davey M Smith; Susan J Little; Douglas A Lauffenburger; Douglas D Richman; Galit Alter
Journal:  AIDS       Date:  2018-02-20       Impact factor: 4.177

8.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

Review 9.  Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Authors:  Margaret E Ackerman; Galit Alter
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

10.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.